Dasatinib Active Not Recruiting Phase 2 Trials for Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01310010Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia